Галоперидол

Quick links to important sections

Галоперидол

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Галоперидол

Quick Facts

Property Description
Active ingredient Haloperidol Decanoate
Form Solution for Depot Injection
Pharmacological class First-Generation Antipsychotic (Neuroleptic)
Common Use Management of chronic psychotic symptoms
Origin Synthetic (Butyrophenone derivative)

Галоперидол Decanoate: Classification and Chemical Origin

Галоперидол Decanoate is a synthetic medicine classified as a first-generation antipsychotic agent, frequently referred to as a neuroleptic. The drug is a high-potency agent belonging to the butyrophenone chemical family, a class supported by decades of clinical use. The active ingredient, Haloperidol Decanoate, is chemically modified as an ester derived from the base drug Haloperidol. This INN formulation is clinically recognized for its efficacy in stabilizing major disturbances in thought and perception and is included on the World Health Organization’s Model List of Essential Medicines.

The Depot Formulation and Composition

This medication is consistently manufactured as a single-ingredient long-acting depot formulation, designed exclusively as a solution for intramuscular injection. The formulation's primary differentiating feature is its composition: the active ingredient is dissolved in a pharmaceutical grade vegetable oil base, typically sesame oil, along with a preservative like benzyl alcohol. This oily medium allows the compound to be slowly released over an extended period. The resulting depot injection is specifically utilized for patient groups requiring highly reliable, consistent drug levels without the necessity of daily oral administration, a key factor in improving long-term care adherence.

Core Function: The Purpose of Dopamine Antagonism

The general function of Галоперидол Decanoate is achieved through its potent role as a dopamine D2-receptor antagonist in the central nervous system. This sustained blocking action regulates excessive activity of the neurotransmitter dopamine, which contributes to disorganized mental states. The ultimate purpose of this medication is to promote enduring psychological stability by consistently mitigating severe psychotic symptoms. The extended duration of effect achieved by the depot form supports continuous symptom control, which is essential for patients managing chronic conditions.

Regulatory References

  1. WHO Model List of Essential Medicines: Haloperidol decanoate

What side effects are possible with Галоперидол?

Possible Side Effects and Safety Information

The regulatory safety profile of Haloperidol Decanoate is primarily characterized by the risk of Extrapyramidal Symptoms (EPS), which are documented as very common adverse reactions. This classification includes neurological effects such as parkinsonism, akathisia, and dystonia, often appearing early in treatment or after dose adjustments.


System-Organ Classes and Frequency

Adverse reactions are formally categorized by the affected body system, according to official labeling:

System-Organ Class Frequency Note Key Documented Effects (Examples)
Nervous System Very Common EPS, Headache, Agitation
Cardiac Disorders Common / Rare Tachycardia, QTc Prolongation
Gastrointestinal Common Constipation, Dry Mouth

Serious Adverse Reactions

The regulatory documents highlight rare but clinically critical events. These include Neuroleptic Malignant Syndrome (NMS), a severe, potentially fatal neurological condition, and Tardive Dyskinesia, a syndrome of potentially irreversible involuntary movements that increases in risk with long-term exposure. The medication is also associated with the serious risk of QTc interval prolongation and subsequent ventricular arrhythmias.


Population-Specific Safety Constraints

Official labeling includes specific constraints for certain groups. The use of this antipsychotic is contraindicated in individuals with conditions like Parkinson’s disease or a known prolonged QTc interval. Furthermore, it is officially documented that this class of medication is associated with an increased risk of death and cerebrovascular adverse reactions in older patients with dementia-related psychosis.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Profile

Overdose manifestations are primarily described in regulatory documents as an exaggeration of pharmacological effects, focusing on severe central nervous system (CNS) and cardiovascular disturbances.

Element Official Regulatory Description
Documented Manifestations Symptoms include severe toxic CNS depression, coma, and exaggerated Extrapyramidal Symptoms (EPS) such as muscle rigidity and tremor [FDA Label Information].
Life-Threatening Risks The primary critical risk is QTc interval prolongation, which can lead to Torsades de Pointes and sudden death. Neuroleptic Malignant Syndrome (NMS), characterized by hyperpyrexia and autonomic instability, is a potentially fatal outcome [EMA therapeutic overview].
When to Seek Urgent Help Seek immediate medical attention or contact emergency services if severe manifestations occur, such as collapse, seizures, trouble breathing, or inability to be awakened [MedlinePlus Drug Information].

Official regulatory guidance mandates that if NMS is suspected, or if the QTc interval is found to exceed 500 milliseconds, the drug must be immediately discontinued. Management requires continuous ECG monitoring and symptomatic and supportive treatment, as no specific antidote is known. Procedures include the use of antiparkinsonian agents for severe EPS and pressor agents for managing hypotension, while avoiding epinephrine.

Therapeutic Uses of Галоперидол

The therapeutic role of this long-acting antipsychotic generally involves supporting long-term management in individuals with chronic conditions. It is applied across therapeutic domains involving severe mental and behavioral dysregulation and assists with maintaining functional stability. This medication is commonly used in conditions characterized by periods of heightened symptoms, including schizophrenia and schizoaffective disorder, which are major therapeutic indications. The depot injection is relevant for the maintenance treatment of these chronic conditions.

It is considered relevant in clinical settings marked by heightened patient distress and is used to ease challenging manifestations of psychomotor agitation and severe behavioral dysregulation. The medication supports the management of symptom clusters that may become intense or disruptive, such as hallucinations, delusions, and explosive hyperexcitability. A secondary domain involves addressing involuntary movement and vocal disorders, particularly complex tics seen in Tourette syndrome.

“This approach provides support that helps ease the overall symptom burden and offers symptomatic relief that assists with maintaining functional stability.”

By helping to moderate these distressing symptoms, the treatment contributes to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases.

Clinical Focus: Symptom Management
Primary Focus Severe behavioral and thought disorders
Key Benefit Supports general well-being and improved comfort
Use Context Applied in long-term maintenance scenarios
Symptom Type Positive psychotic phenomena and complex motor tics

Eligibility and Restrictions for Use

Official Population Eligibility for Галоперидол Decanoate

Regulatory documentation defines strict inclusion and exclusion criteria for the use of this long-acting injection.

Age and Condition-Related Eligibility Official Regulatory Status
Adults (18 years and older) Permitted population for maintenance treatment.
Children and Adolescents (under 18) Use not established; generally not recommended (efficacy and safety data are lacking for the depot formulation).
Older Adults (Geriatric) Requires caution and a lower initial dose. Not approved for dementia-related psychosis.

Absolute Contraindications (Do Not Use)

The medicine is formally prohibited in individuals with the following documented conditions:

  • Severe toxic central nervous system (CNS) depression or comatose states.
  • Parkinson’s disease or Dementia with Lewy Bodies.
  • Known QTc interval prolongation or a family history of congenital long QT syndrome.
  • Significant cardiac disease, including recent acute myocardial infarction or uncompensated heart failure.
  • Uncorrected electrolyte imbalances such as hypokalemia or hypomagnesemia (correction is mandatory prior to administration).
  • Hypersensitivity to haloperidol or to any excipients (e.g., sesame oil).

Conditional or Restricted Use

Caution is required for other specific populations, as indicated by regulatory labels:

  • Hepatic Impairment: Caution is necessary due to extensive liver metabolism; some labels recommend halving the initial dose.
  • Pregnancy and Lactation: Generally not recommended as a precautionary measure, and exposure in the third trimester is associated with risks of extrapyramidal and/or withdrawal symptoms in the neonate. Use during breastfeeding is also not recommended.
  • Seizure History: Caution is advised for patients with a history of seizures or epilepsy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Haloperidol's interaction profile involves both effects on heart function and metabolic pathways. Co-administration with other drugs known to prolong the QTc interval is generally contraindicated due to an increased risk of severe cardiac arrhythmias, including Torsades de Pointes. This risk is heightened with higher-than-recommended doses or when electrolyte disturbances are present.

The medication is metabolized primarily by the liver enzymes CYP3A4 and CYP2D6. Consequently, potent inhibitors of these enzymes (e.g., certain antidepressants or antifungals) can increase haloperidol blood concentrations, potentially leading to increased side effects. Conversely, potent inducers (e.g., carbamazepine, rifampin) can decrease haloperidol levels, which may reduce its effectiveness. Dose adjustments may be necessary with these combinations.

Combined use with Lithium has been associated with a potential, though not definitively established, risk of an encephalopathic syndrome characterized by neurological toxicity; patients on this combination require close monitoring. Haloperidol can also potentiate the effects of CNS depressants, including alcohol, sedatives, and opioids, and may impair the effectiveness of dopaminergic medications like levodopa. Epinephrine should not be used to treat haloperidol-induced hypotension, as haloperidol may block its vasopressor activity.

Mechanism of Action

Галоперидол acts as a high-affinity competitive antagonist at the mathbfDmathbf2 dopamine receptor subtype, particularly within the mesolimbic pathway. The D2 receptor is a G-protein-coupled receptor that, upon agonist binding, typically inhibits adenylyl cyclase, reducing intracellular cyclic AMP (cAMP) levels. By blocking the D2 receptor, Галоперидол prevents this inhibitory effect, resulting in the modulation of mathbfcAMP signaling and the stabilization of hyperactive dopaminergic transmission.

The drug also exhibits significant antagonism at the 5-mathbfHT2mathbfA serotonin receptor. This interaction contributes to a broader modulation of serotonergic signaling in addition to the primary dopaminergic effects. Furthermore, Галоперидол interacts with mathbfDmathbf1 receptors and mathbfalphamathbf1 adrenergic receptors with lower affinity, contributing to the complete pharmacological profile that influences neuronal excitability across multiple central nervous system pathways.

Dosage and Administration Information

Official Administration Guidelines for Галоперидол

The usage of Haloperidol is strictly defined by regulatory guidelines, outlining the required route, dose titration, and administration schedule, which must be followed precisely.

Administration Scope

Guideline Element Official Instruction
Route of Administration Oral (tablet, concentrated liquid/solution) and Intramuscular (IM) injection.
Dosing Schedule Initial dose is typically low and is gradually increased by a healthcare professional over several days (e.g., 1 to 7 days) until the therapeutic maintenance dose is reached.
Frequency of Use Oral forms are generally taken two or three times a day to maintain consistent blood levels. The liquid formulation must be measured using the provided, calibrated dropper.
Timing with Meals Tablets or liquid may be taken without regard to food. The concentrated oral solution can be mixed with beverages such as orange juice, cola, or tomato juice, and should be taken immediately.
Duration of Therapy Treatment must not be stopped suddenly. The dosage must be gradually decreased by a doctor if discontinuation is necessary.

Specific Patient Populations

Official instructions require special consideration for age-specific use:

  • Elderly Patients: The recommended initial dose for all indications is half of the lowest adult dose, often 0.5 mg/ day for certain conditions. Dose adjustments must be careful and gradual, and the maximum daily dose is 5 mg/ day, unless higher doses are medically justified.
  • Children (3-12 years): Initial oral dose is typically 0.5 mg/ day in two to three divided doses, increasing by small 0.5 mg increments at 5- to 7-day intervals.

Missed Dose Instructions

If a dose is missed, it should be taken as soon as possible, unless it is almost time for the next dose. In that case, the missed dose must be skipped, and the regular schedule resumed. Do not take a double dose to compensate for a missed dose.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Clinical evidence for haloperidol, a first-generation (typical) antipsychotic, primarily focuses on its established use in treating schizophrenia, psychosis-induced agitation, and delirium. Recent studies largely seek to clarify its effectiveness relative to newer, atypical antipsychotics and to better characterize its safety profile, particularly in vulnerable populations.


Efficacy in Acute Agitation and Psychosis

Haloperidol remains a widely utilized option for the rapid tranquilization of patients experiencing acute agitation or aggression associated with psychosis. Systematic reviews comparing haloperidol with other agents (such as lorazepam or atypical antipsychotics) in this setting often highlight its rapid action, though some studies note varying results in achieving full sedation or restful sleep within the first two hours. Research has also investigated the route of administration, suggesting that intravenous and intramuscular haloperidol may have comparable effectiveness over several hours.


Safety Profile and Movement Disorders

Due to its mechanism of action, haloperidol is associated with a higher risk of extrapyramidal symptoms (EPS), including acute dystonia, parkinsonism, and tardive dyskinesia (TD). Recent observational data reinforces the need for caution, particularly regarding long-term use and in elderly women, who may face an increased risk of TD. Furthermore, clinical trials continue to monitor for serious, rare side effects such as QTc-interval prolongation, which requires vigilance, especially when the medication is administered intravenously or at higher doses.


Delirium Management

While haloperidol has historically been the standard drug for managing hyperactive delirium, recent umbrella reviews suggest limited conclusive evidence of its efficacy in preventing or fully resolving delirium symptoms. These reviews often recommend focusing future research on specific behavioral endpoints, such as agitation and hallucinations, rather than the overall resolution of delirium. Caution is specifically advised when using haloperidol in patients with Parkinson's disease or dementia with Lewy bodies, as it can worsen motor symptoms and is linked to increased mortality in this population.

Frequently Asked Questions (FAQ)

Common questions about Галоперидол (FAQ)

Q: Is Галоперидол an anti-anxiety medicine?

A: Галоперидол is classified as a first-generation antipsychotic medicine. It is officially approved for use in conditions that involve severe agitation and certain psychotic symptoms. Agitation is one of the conditions for which the medicine is indicated, but it is not primarily classified as an anti-anxiety drug.


Q: How quickly can someone expect to feel the initial effects of Галоперидол?

A: According to official patient information, the tablets and liquid formulations of Галоперидол are generally described as beginning to work within approximately 1 to 2 hours after administration.


Q: Is it true that Галоперидол causes tremors or shaking?

A: Yes, official regulatory safety information indicates a risk of movement-related side effects known as Extrapyramidal Symptoms (EPS). These symptoms can include involuntary shaking (tremors), muscle stiffness, and other effects similar to parkinsonism.


Q: What is the duration of action for a single dose of Галоперидол?

A: The duration of effect is often measured by the drug's half-life, which is the time it takes for the concentration in the body to be reduced by half. For a single oral dose, the half-life of haloperidol is generally reported to range from approximately 14.5 to 36.7 hours.


Q: Can Галоперидол cause changes in body weight?

A: Official documents list changes in body weight as a possible side effect of the medication. Specifically, weight gain is a documented adverse reaction associated with the use of Галоперидол.


Q: Is there a known risk of dependence or addiction with Галоперидол?

A: Галоперидол is not classified as a controlled substance with a high potential for abuse or addiction under regulatory acts like the U.S. Controlled Substances Act. However, regulatory information indicates that treatment should be discontinued gradually under the supervision of a healthcare provider, rather than stopping suddenly.


Q: Does taking Галоперидол affect a person's ability to drive or operate machinery?

A: Yes, official warnings advise against driving or operating complex machinery if the medication causes certain side effects. This caution is necessary if the user experiences drowsiness, dizziness, or blurred vision.


Q: Is Галоперидол described as a sedative?

A: The drug's primary classification is as an antipsychotic. However, sedation (drowsiness or sleepiness) is commonly listed as an adverse reaction in official regulatory documents due to its effect on the central nervous system.


Q: Can Галоперидол cause difficulty sleeping or insomnia?

A: Yes, according to official regulatory documents, difficulty sleeping or insomnia is documented as a possible adverse reaction associated with the use of this medication.


Q: Is there information on how Галоперидол affects cognitive function or memory?

A: As a medicine that affects the central nervous system, Галоперидол may cause effects like somnolence or dizziness. These reactions can lead to a general impairment of mental and physical abilities needed for cognitive tasks.


Q: Does Галоперидол affect blood pressure?

A: Yes, changes in blood pressure are a documented side effect. Official documents commonly list a risk of hypotension (low blood pressure), particularly orthostatic hypotension, which is a drop in blood pressure when moving to a standing position.


Q: Is it true that prolonged use of Галоперидол requires periodic re-evaluation?

A: Due to the potential risks associated with long-term exposure, particularly the increased risk of Tardive Dyskinesia, official documents note that the duration and need for continued therapy should be regularly assessed by a healthcare provider.


Q: Are there any known interactions between Галоперидол and nicotine products?

A: Yes, smoking can affect the way the body processes the medication, potentially leading to a change in haloperidol levels. Official sources note that a change in smoking status may affect drug levels, and this should be monitored by the prescribing healthcare provider.


Q: What should be done if a user feels the medicine is not working?

A: The principle of administration described in guidelines involves starting at a low dose and adjusting it gradually by a healthcare professional until a therapeutic effect is observed.


Q: Do studies suggest that the effects of Галоперидол vary significantly among different people?

A: Official documents describe that the medication is metabolized by liver enzymes that can vary between people, and administration guidelines mandate that the dose must be adjusted based on the individual's response and tolerability.


Q: Are there any specific foods or drinks to avoid while using Галоперидол?

A: Official information notes that alcohol consumption may increase the drug’s effects on the central nervous system, and patients are typically cautioned regarding its use. The concentrated oral solution, if used, is generally allowed to be mixed with specific beverages like orange juice, cola, or tomato juice.


Q: Do herbal supplements interact with Галоперидол?

A: Haloperidol is processed by specific liver enzymes, and some herbal supplements can interfere with these enzymes. Official warnings emphasize that this medication can be affected by other substances, which is why official labeling highlights the need to account for all concurrent medicines and supplements.


Q: Is it safe to take over-the-counter pain relievers while using Галоперидол?

A: Regulatory documents warn that haloperidol can potentiate the effects of central nervous system (CNS) depressants. Certain over-the-counter medicines may also have CNS depressant properties, and regulatory documents describe that the combination requires consideration due to the potential for increased CNS depressant effects.


Q: What research is available regarding the use of Галоперидол in women who are pregnant or breastfeeding?

A: The medicine is generally not recommended during pregnancy and lactation due to official warnings. This is based on documented risks, including reports of movement-related and/or withdrawal symptoms in newborns whose mothers were exposed in the third trimester.


Q: How long does it typically take for potential side effects to show up after starting Галоперидол?

A: The onset of side effects varies. For instance, involuntary movement symptoms (EPS) often appear early in treatment or following a dose change. Conversely, the risk of serious side effects like Tardive Dyskinesia increases with prolonged exposure.


Q: Is it possible for Галоперидол to cause blurry vision?

A: Yes, regulatory documents list blurred vision as a possible adverse reaction. This is often noted under the general category of nervous system disorders.


Q: Can using Галоперидол cause changes in body temperature?

A: The medication is associated with the rare but serious risk of Neuroleptic Malignant Syndrome (NMS). This syndrome is characterized by a high fever (hyperthermia) as a key symptom, which indicates an issue with body temperature regulation.

How should Галоперидол be stored and disposed of?

How to Store and Dispose of Haloperidol

Official regulatory documentation mandates specific conditions for storing and disposing of Haloperidol to ensure product stability and safety.

Storage Requirements

Haloperidol must be stored at Controlled Room Temperature, typically maintained between 15 C and 30 C (59 F and 86 F). The injection solution must not be frozen.

Protection from light is required; therefore, the medicine must be kept in its original container or outer carton. For safety, all formulations must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Haloperidol must not be disposed of via wastewater or mixed with routine household trash. Disposal of the unused product and associated waste material must be carried out in accordance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Галоперидол found in:

A-Z Index: